AMRX
Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026
Article Summary
HOLD- Amneal Pharmaceuticals Inc. (Nasdaq: AMRX) announced that Chirag Patel, Co-Chief Executive and President, will participate and present at Goldman Sachs 47th Annual Global Healthcare Conference 2026 being held on June 8-10 at Loews Miami Beach Hotel in Miami, FL.
- The diversified biopharmaceutical leader focused on expanding access to affordable and innovative medicines founded in 2002 by brothers and co-CEOs.
- Amneal has diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines delivering more than 160 million prescriptions annually, primarily in the United States.
- Amneal Pharmaceuticals presentation will take place on Tuesday June 9, 2026 at 8:40AM EDT with a live webcast of the presentation available here.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 7.6% | 25% | 35.0 ptsBelow Screener (7.6%) - Weak growth |
| EPS Growth Next 5Y ? | 17.2% | 25% | 50.0 ptsMeets Minimum (17.2%) - Passes screener |
| Target Price Upside ? | 33.1% | 20% | 85.0 ptsLarge Upside (33.1%) - Target: $17.20 vs Current: $12.92 |
| Gross Margin % ? | 38.7% | 15% | 60.0 ptsSolid (38.7%) - Decent margins |
| Drawdown from 52-Wk High ? | -16.2% | 15% | 40.0 ptsMild Pullback (-16.2%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About AMRX
- Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally.
- The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.
- The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals.
- The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease.
- This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease.
- The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs.
- This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers.
- It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies.
- The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018.
- Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.